We are live on
!
Find out more
FM
Frazier Management Portfolio holdings
AUM
$1.12M
1-Year Est. Return
151.58%
This Fund
S&P 500
This Quarter
Est. Return
-25.8%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$388M
AUM Growth
-$159M
(-29%)
Cap. Flow
+$19.4M
Cap. Flow
% of AUM
5.02%
Top 10 Holdings %
Top 10 Hldgs %
90.41%
Holding
17
New
1
Increased
1
Reduced
2
Closed
–
Avg Time Held
4.5
quarters
Top 10 Avg Time Held
5.3
quarters
Top 20 Avg Time Held
4.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tempest Therapeutics
TPST
|
+$14.7M |
| 2 |
Krystal Biotech
KRYS
|
+$5.23M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
|
+$525K |
| 2 |
Gritstone bio, Inc. Common Stock
GRTS
|
+$76 |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
AnaptysBio
ANAB
$1.36B
| $148M | 38.13% |
2,316,447
| – | – |
2017 Q1
7 quarters
|
|
|
APTX
2
DELISTED
Aptinyx Inc. Common Stock
APTX
| $52.8M | 13.61% |
3,190,079
| – | – |
2018 Q2
2 quarters
|
|
3
Collegium Pharmaceutical
COLL
$701M
| $32.4M | 8.36% |
1,887,332
| – | – |
2015 Q4
12 quarters
|
|
|
4
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $31.9M | 8.22% |
2,061,758
-4
| -0% | -$76 |
2018 Q3
1 quarter
|
|
5
Iovance Biotherapeutics
IOVA
$6.57B
| $19.4M | 5% |
2,188,331
| – | – |
2016 Q2
10 quarters
|
|
|
6
Krystal Biotech
KRYS
$9.51B
| $18.2M | 4.69% |
875,000
+250,000
| +40% | +$5.23M |
2018 Q3
1 quarter
|
|
|
ALNA
7
DELISTED
Allena Pharmaceuticals
ALNA
| $18.2M | 4.68% |
3,330,373
| – | – |
2017 Q4
4 quarters
|
|
|
8
Tempest Therapeutics
TPST
$11.5M
| $11.1M | 2.86% |
+7,162
| New | +$14.7M |
2018 Q4
0 quarters
|
|
|
SRRA
9
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $10.7M | 2.76% |
202,803
| – | – |
2015 Q4
12 quarters
|
|
10
DELISTED
Alpine Immune Sciences Inc
ALPN
| $8.09M | 2.09% |
2,199,011
| – | – |
2017 Q3
5 quarters
|
|
11
DELISTED
Iterum Therapeutics
ITRM
| $7.71M | 1.99% |
102,554
| – | – |
2018 Q2
2 quarters
|
|
12
DELISTED
Synlogic
SYBX
| $6.07M | 1.57% |
57,694
| – | – |
2018 Q1
3 quarters
|
|
13
DELISTED
Kezar Life Sciences
KZR
| $5.9M | 1.52% |
25,000
| – | – |
2018 Q2
2 quarters
|
|
|
NBRV
14
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $5.86M | 1.51% |
16,049
-977
| -6% | -$525K |
2018 Q3
1 quarter
|
|
|
ETTX
15
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
| $5.49M | 1.42% |
1,349,953
| – | – |
2018 Q3
1 quarter
|
|
16
DELISTED
Cidara Therapeutics
CDTX
| $3.08M | 0.8% |
65,613
| – | – |
2015 Q4
12 quarters
|
|
|
BLCM
17
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $3.07M | 0.79% |
105,144
| – | – |
2018 Q2
2 quarters
|
|
Similar funds
ACMV
FRCMI
DB
NAM
AP
ID
CI
DIF
Frazier Management's Q4 2018 Portfolio in Review
As of Q4 2018, Frazier Management held 17 positions worth $388M, down 29% from $546M the previous quarter. Its ten largest holdings account for 90% of the portfolio.
Frazier Management deployed $19.4M of net new capital in Q4 2018, opening 1 new position and adding to 1 existing holding. Its largest new stake was Tempest Therapeutics: 7,162 shares worth $11.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Nabriva Therapeutics plc Ordinary Shares Ireland, an estimated $525K trimmed.
- Frazier Management's largest Q4 2018 buy was Tempest Therapeutics: 7,162 shares worth $11.1M.
- Frazier Management added most to Krystal Biotech in Q4 2018, an estimated $5.23M increase.
- Frazier Management's biggest Q4 2018 reduction was Nabriva Therapeutics plc Ordinary Shares Ireland, cutting an estimated $525K.
- Frazier Management's ten largest holdings make up 90% of its $388M portfolio in Q4 2018.
- Frazier Management opened 1 new position and closed 0 in Q4 2018.
- Frazier Management's portfolio value fell 29% quarter-over-quarter to $388M.
Based on Frazier Management's 13F filing for Q4 2018, filed 11 Feb 2019.